Authors

Reimagining Established Drugs Medicines Could Lead to Potential New Applications

The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.

Half of Pharmacy Technicians Feel Fulfilled in Their Current Role

The Connecticut Society of Health-System Pharmacists Technician Committee survey explores the perception of career growth opportunities and challenges.

Exploring the Antidepressant Potential of GLP-1 Receptor Agonists

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Dogs share a number of cancers with humans, including melanoma, non-Hodgkin lymphoma, leukemia, and osteosarcoma.

Exploring the Vascular Benefits of Semaglutide in Peripheral Artery Disease

Marc Bonaca, MD, PHH, FACC discussed semaglutide’s potential benefits for non-diabetic patients with peripheral artery disease.

Finerenone Shows Promise in Heart Failure and Kidney Disease Management

John Ostrominski, MD shares insights into the safety and efficacy of finerenone, based on data from the FINEARTS-HF trial.

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

BV-R2 combination shows survival benefit across high-risk subgroups.

Community Pharmacists Can Advance Vaccination in Cancer Care

Pharmacists should leverage their accessibility to boost immunization rates among individuals undergoing cancer treatment.

Driving Clinical Pharmacy Development With Data-Driven Metrics and Insights

There are no clearly defined, widely accepted clinical pharmacist metrics.

An Overview of Vitamins and Supplements in Multiple Sclerosis

By examining the evidence, pharmacists can gain insights into whether these supplements could be integrated into MS treatment regimens to improve patient outcomes.

Subcutaneous Pembrolizumab Matches IV in Lung Cancer Trial

Enriqueta Felip, MD, PhD, discussed the benefits of subcutaneous pembrolizumab for patients with metastatic non–small cell lung cancer.

Immune Checkpoint Inhibitor-Associated Nephritis: A Case of Nivolumab-Induced Acute Kidney Injury in a Patient with Urothelial Carcinoma

This case highlights the importance of recognizing ICPI-AKI, implementing effective therapeutic interventions, and understanding the clinical context to prevent irreversible renal damage.

Going with the Flow: Updates in Diabetes and Chronic Kidney Disease

CKD is a complication of diabetes. Emerging treatments aim to optimize management and reduce risks. Pharmacists are key in applying new evidence to clinical practice.

Risks and Impacts of Cannabis Use During Pregnancy: A Growing Concern for Neonatal Health

Cannabis use during pregnancy may harm fetal development and long-term health.

The Return of Belantamab Mafodotin: Past Lessons, Present Promise, and Future Impact

Nuclear Isotopes Could Help Address Challenges in Oncology Clinical Trials

The radiation emerging from these isotopes can be used in 2 different ways in cancer trials: imaging (detection of tumors) and therapy (destruction of tumors).

TAR-200 Demonstrates Strong Efficacy and Favorable Tolerability in BCG-Unresponsive NMIBC

At ESMO 2025, Felix Guerrero-Ramos, MD, discussed SunRISe-1 data showing durable responses and low toxicity with TAR-200, the importance of training in device management, and how future biomarker research may refine patient selection and combination strategies.

Five Domains, One Outcome: How Social Factors Shape Cancer Survival

Iman Ahmed, PharmD, BCOP, shared key insights about how social determinants of health impact treatment access and outcomes for patients with leukemia.

In a Nod to Precision Oncology, the FDA Approves Revumenib

The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.

Pharmacists Reimagine Myeloma Care With Insights from ASCO

Gabe Hinojosa, PharmD, BCOP, shares key data for pharmacists from the 2025 American Society of Clinical Oncology Annual Meeting.

Pharmacists Can Advance Lung Cancer Screening Awareness in High-Risk Patients

Pharmacists can help close the lung cancer screening gap by identifying high-risk tobacco users, increasing awareness, and connecting eligible patients to lifesaving early detection.

Navigating Weight Loss Medications: Long-Term Use, Discontinuation, and Maintaining Weight Loss

A holistic approach emphasizing lifestyle modifications is essential to maintain weight loss after and while stopping medication.

Medical Misinformation Affects Public Understanding of Long COVID

Pharmacists Help Guide Regimen Choice Between Flu/Cy/TBI and Flu/Bu2

Monica Sawiris, PharmD, said there were noticeable differences in toxicities between each regimen.

Outcomes of Pharmacist-Driven Clinical Interventions in a Medically Integrated Oncology Specialty Pharmacy Practice

The high acceptance rates of these interventions demonstrate the key role in optimizing patient care that clinical oncology pharmacists with access to medical records play.

Cost Avoidance and Satisfaction Associated With Clinical Pharmacy Services in a Veterans Affairs Specialty Clinic

An infusion and specialty clinical pharmacist is a valuable integrated member of the health care team as demonstrated by cost avoidance and high satisfaction reported by both veterans and specialty providers.

Pharmacists Can Advance Lung Cancer Screening Awareness in High-Risk Patients

Pharmacists can help close the lung cancer screening gap by identifying high-risk tobacco users, increasing awareness, and connecting eligible patients to lifesaving early detection.

What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise

Exclusive insights from Ned Milenkovich, PharmD, JD, help parse what pharmacists should be aware of as most favored nation initiatives are agreed upon with the federal government.

Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events

Full results detailing the safety and efficacy of enlicitide decanoate, an oral PCSK9 inhibitor, were published in The New England Journal of Medicine.

Oral Semaglutide Approved to Reduce the Risk of Cardiovascular Events

The FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).